Cullinan Therapeutics, Inc.

Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results

CLN-978 (CD19 TCE) multi-dose regimen data in SLE, RA, and Sjögren’s disease will be shared in December